Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy

Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy

ObjectiveThis study assessed the efficacy of INV-202, a novel peripherally restricted cannabinoid type-1 receptor (CB1R) inverse agonist, in a streptozotocin-induced type-1 diabetes nephropathy mouse model.MethodsDiabetes was induced in 8-week-old C57BL6/J male mice via intraperitoneal injection of...

Full description

Bibliographic Details
Main Authors: Laetitia Jacquot, Océane Pointeau, Célia Roger-Villeboeuf, Patricia Passilly-Degrace, Rim Belkaid, Isaline Regazzoni, Julia Leemput, Chloé Buch, Laurent Demizieux, Bruno Vergès, Pascal Degrace, Glenn Crater, Tony Jourdan
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Nephrology
Subjects:
nephropathy
diabetes
CB1 receptors
inverse agonism
peripherally-restricted
fibrosis
Online Access:https://www.frontiersin.org/articles/10.3389/fneph.2023.1138416/full

Internet

https://www.frontiersin.org/articles/10.3389/fneph.2023.1138416/full

Similar Items